Full Press Release Details
Pharmaceuticals Reports Positive Results from a Study of Oral Insulin Capsule on
Type 1 Diabetic Patients
Israel - July 21, 2009- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)
(http://www.oramed.com), a developer of alternative drug delivery
systems, today reported positive results from a Phase 2A study of its
oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of
this study marks Oramed's first clinical trial on patients with Type 1 Diabetes
Mellitus, whereas, all Oramed's trials up to date have been conducted
on type 2 diabetic patients. This study evaluated safety, tolerability, and food
effects in type 1 diabetic patients.
oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious
adverse events were observed. The insulin absorption was not affected when
given before meal ingestion.
Chief Scientific Officer, Miriam Kidron, PhD., remarked, "These results
demonstrate that Oramed's oral insulin capsule had a good safety profile and was
effective on patients with type 1 diabetes when taken prior to a
Oramed is conducting its Phase 2B clinical trial in South Africa, in which the
company is evaluating the effects of ORMD-0801 on type 2 diabetic
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
information, please visit www.oramed.com
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and the company's ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company's filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
and Investor Relation Contacts:
Email: tara@oramed.com